SINGAPORE, May 05, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (NASDAQ:CUPR) ("Cuprina" or "the Company"), a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds and infertility, as well as cosmeceuticals for the health and beauty sector, today announced it had, on April 6, 2025, completed construction of, and obtained ISO 13485 certification and a dealer license for, an operational in-vitro fertilization ("IVF") media production facility in Singapore. The ISO 13485 certification, which validates that Cuprina's quality management system at the facility meets internationally agreed standards

6-K - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)

NT 20-F - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)